Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey.

Plüß, Marlene; Chehab, Gamal; Korsten, Peter

Plüß, Marlene; Chehab, Gamal; Korsten, Peter.

Plüß M; Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.
Chehab G; Department of Rheumatology & Hiller-Research Unit Rheumatology, Heinrich-Heine University, Duesseldorf, Germany.
Korsten P; Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany peter.korsten@med.uni-goettingen.de.

Ann Rheum Dis ; 80(4): e52, 2021 04.

Article in English | MEDLINE | ID: covidwho-1909648

Subject(s)

COVID-19 Drug Treatment; Lupus Erythematosus, Systemic; Humans; Hydroxychloroquine/adverse effects; Lupus Erythematosus, Systemic/drug therapy; Lupus Erythematosus, Systemic/epidemiology; Pandemics

Keywords

epidemiology; hydroxychloroquine; lupus erythematosus, systemic

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment / Lupus Erythematosus, Systemic Type of study: Observational study Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2021 Document Type: Article Affiliation country: Annrheumdis-2020-217967

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google